Editor's Review,have been recommended by NICE since 2022

The growing prevalence of obesity has spurred significant research into effective treatment modalities. Among the most promising advancements are glucagon-like peptide-1 (GLP-1) receptor agonists. These innovative therapies, initially developed for type 2 diabetes mellitus (T2DM), have demonstrated remarkable efficacy in promoting weight loss and managing obesity. This article delves into the mechanisms, benefits, and considerations surrounding GLP-1-based therapies for obesity.

Understanding GLP-1 and its Role in Weight Management

Glucagon-like peptide-1 (GLP-1) is an incretin hormone naturally produced in the gut in response to food intake. It plays a crucial role in glucose homeostasis by stimulating insulin secretion and inhibiting glucagon release. Beyond its metabolic effects, GLP-1 also influences appetite and satiety.

GLP-1 receptor agonists (RAs) are a class of medications designed to mimic the actions of the natural GLP-1 hormone. By activating GLP-1 peptides, these medications affect body weight in multiple ways. They work by:

* Inhibiting glucagon release: This reduces the liver's production of glucose.

* Stimulating insulin release: This helps lower blood sugar levels.

* Slowing gastric emptying: This leads to a feeling of fullness for longer periods.

* Acting on brain and gut receptors: This helps curb cravings and promotes a sense of satiety, leading to reduced food intake.

These combined actions contribute to a significant reduction in body weight. Research has consistently shown that GLP-1 RAs provide clinically meaningful weight loss. For instance, studies indicate that GLP-1 RAs used for weight reduction in people with overweight and obesity can result in a net benefit in achieving substantial weight loss. A systematic review found that non-diabetic patients with obesity who received glucagon-like peptide-1 receptor agonists (GLP-1RAs) experienced significant decreases in weight, BMI, and waist circumference. The efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference is a key factor driving their increased use.

Efficacy and Clinical Outcomes

The effectiveness of GLP-1 agonists in promoting weight loss is well-documented in both preclinical and clinical studies. These GLP-1-based therapies represent highly effective treatment options for individuals struggling with obesity. For example, semaglutide, a prominent GLP-1 RA available under brand names like Ozempic, Wegovy, and Rybelsus, has been recommended by NICE since 2022 and promises to reduce weight by over 10%. Clinical trials have demonstrated that mean bodyweight was reduced between baseline and week 68 in participants receiving semaglutide in various dosages.

Furthermore, GLP-1 drugs influence more than the gut and the weight. Emerging research suggests they may also have positive impacts on cardiovascular health, brain function, and bone and muscle health. The WHO Guideline on GLP-1 Therapies for Obesity in Adults highlights the broad metabolic benefits provided by these treatments.

Who is a Candidate for GLP-1 Therapies?

According to the FDA, GLP-1s are approved for people with obesity (BMI of 30 or higher). However, individuals with a BMI of 27 or higher who also have at least one weight-related comorbidity, such as hypertension or dyslipidemia, may also be considered suitable candidates. The decision to prescribe GLP-1 agonists for obesity is typically made by a healthcare professional based on an individual's medical history and specific needs.

Specific GLP-1 Agonists for Weight Loss

Several GLP-1 agonists are available for managing overweight and obesity. Notably, Wegovy and Saxenda are specifically approved for weight management. These are often administered via injection medications.

Potential Side Effects and Risks

While GLP-1RAs are effective in managing obesity, their use is associated with potential side effects. The most common adverse events are gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation. These are often transient and can be managed by adjusting the dosage. However, rare but serious adverse events have also been reported, underscoring the importance of medical supervision.

Beyond GLP-1: Emerging Therapies

The field of obesity treatment is rapidly evolving. Research is exploring novel agents, including those that act on multiple hormones. For instance, some new obesity drugs are being developed that mimic the actions of three hormones: glucose-depending insulinotropic polypeptide (GIP), GLP-1, and glucagon. The GIP hormone can help you feel fuller, control blood sugar, and aid in weight loss when paired with a GLP-1 in dual GIP/GLP-1 agonists. This indicates a future where combination therapies may offer even